AstraZeneca: positive results in solid tumours
(CercleFinance.com) - On Monday AstraZeneca and its Japanese partner Daiichi Sankyo announced positive results from a phase II clinical trial of Enhertu, the anti-cancer drug they are jointly developing.
The trial achieved its objective response rate goal by demonstrating a "durable" response in patients with tumours expressing the HER2 gene.
This phase II study is designed to evaluate the efficacy and safety of Enhertu in difficult-to-treat cancers such as bladder, ovarian, pancreatic and other rarer cancers.
Enhertu is one of a new class of molecules, drug-antibody conjugates, which are taken up by tumour cells before the antibody delivers the drug, which then destroys the cancer cell from within.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The trial achieved its objective response rate goal by demonstrating a "durable" response in patients with tumours expressing the HER2 gene.
This phase II study is designed to evaluate the efficacy and safety of Enhertu in difficult-to-treat cancers such as bladder, ovarian, pancreatic and other rarer cancers.
Enhertu is one of a new class of molecules, drug-antibody conjugates, which are taken up by tumour cells before the antibody delivers the drug, which then destroys the cancer cell from within.
Copyright (c) 2023 CercleFinance.com. All rights reserved.